STATES SECURITIES AND EXCHANGE COMMISSION
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
of Report (Date of Earliest Event Reported): September 13, 2018
name of registrant as specified in its charter)
or other jurisdiction of
of principal executive offices)
telephone number, including area code: (206) 325-6086
Former name or former address, if changed since last report
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
7.01. Regulation FD Disclosure
September 13, 2018, Atossa Genetics Inc. (the “Company”) issued a press release announcing preliminary results from
its Phase 1 study of topical Endoxifen in men. Also on September 13, 2018, the Company plans to hold a conference call and present
information about these preliminary results. A copy of the press release and slides for the conference call are attached as Exhibit
99.1 and 99.2, respectively, to this current report and are incorporated herein by reference.
Company is furnishing the information in this Current Report on Form 8-K to comply with Regulation FD. Such information shall
not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company’s
filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before
or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly
set forth by specific reference in such a filing.
harbor” statement under the Private Securities Litigation Reform Act of 1995: Some of the information presented herein may
contain projections or other forward-looking statements regarding future events or the future financial performance of the Company,
which the Company undertakes no obligation to update. These statements are based on management’s current expectations and
are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future
results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates
of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory
clearances, responses to regulatory matters, the market demand for and acceptance of the Company’s products and services,
performance of clinical research organizations and other risks detailed from time to time in the Company’s filings with
the Securities and Exchange Commission, including without limitation its most recent annual report on form 10-K, subsequent quarterly
reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.
item 7.01 above which is incorporated into this Item 8.01 by this reference.
Financial Statements and Exhibits.
Release, dated September 13, 2018
Endoxifen Phase 1 Study in Men Slide Presentation, dated September 13, 2018 |
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
September 13, 2018
Financial Officer, General Counsel and Secretary